Understand your health. Know what to ask.
GLP-1 injection sites: what “rotate” means
Site rotation means changing the exact injection spot. Your product’s device and instructions determine the rest of the routine.
3 sources · FDA, NIHRead · 2 min →
Constipation on GLP-1 tablets: why the formulation matters
Tablets can still cause constipation. The exact product and postpartum factors help explain what needs review.
4 sources · FDA, NIHRead · 2 min →
Hair shedding during GLP-1 treatment: timing and pattern
Hair shedding after weight loss can appear months later. Learn how that differs from gradual pattern hair loss and what the medication labels report.
3 sources · NIHRead · 2 min →
Perimenopause and GLP-1 medicines: clarify the weight and glucose questions
How changing body composition, glucose results and medication eligibility fit together during perimenopause.
4 sources · PubMed / PMC, NIH, The Menopause SocietyRead · 2 min →Weight & MetabolicHow tirzepatide works: GIP and GLP-1, explained
Tirzepatide acts on two hormone receptors involved in appetite and glucose regulation. Here is what that means in plain English.
2 sources · FDA, NIHRead · 2 min →Weight & MetabolicWho can be considered for weight-management medication?
BMI is one part of eligibility. Weight-related conditions, medical history, medicines and the specific product also shape the decision.
2 sources · NIHRead · 2 min →
Who is responsible for a compounded tirzepatide prescription?
The prescriber, dispensing pharmacy and online service have different roles. What to identify before starting a prescription order.
3 sources · FDARead · 2 min →
When GLP-1 treatment changes your appetite, what happens to meals?
A smaller appetite changes meal planning. Food quality, tolerability and enough nutrition still matter, especially when cooking for a household.
2 sources · PubMed / PMC, NIHRead · 2 min →
The first month of GLP-1 treatment: what early progress can look like
Early GLP-1 treatment involves tolerability and changing appetite. Long-term trial averages do not predict a first-month weight result.
2 sources · NIHRead · 2 min →
GLP-1 “microdosing” for maintenance: what is established?
Maintenance trials support continued treatment in specific regimens. They do not establish that any tiny dose or intermittent schedule will preserve results.
6 sources · FDA, NIH, PubMed / PMCRead · 2 min →
Period changes during semaglutide treatment
A returning or changing period does not prove semaglutide has corrected a hormone problem. Cycle history and pregnancy possibility still matter.
3 sources · NIHRead · 2 min →
Semaglutide and a higher resting heart rate
Resting heart rate can rise during semaglutide treatment. A wearable trend is useful context, but symptoms and clinical assessment matter.
1 source · NIHRead · 2 min →